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The nanotechnology capable of high-specificity targeted delivery of anti-neoplastic drugs would be a
significant breakthrough in Cancer in general and Ovarian Cancer in particular. We addressed this
challenge through a new physical concept that exploited (i) the difference in the membrane electric
properties between the tumor and healthy cells and (ii) the capability of magneto-electric nanoparticles
(MENs) to serve as nanosized converters of remote magnetic field energy into the MENs’ intrinsic electric
field energy. This capability allows to remotely control the membrane electric fields and consequently
trigger high-specificity drug uptake through creation of localized nano-electroporation sites. In in-vitro
studies on human ovarian carcinoma cell (SKOV-3) and healthy cell (HOMEC) lines, we applied a 30-Oe d.c.
field to trigger high-specificity uptake of paclitaxel loaded on 30-nm CoFe2O4@BaTiO3 MENs. The drug
penetrated through the membrane and completely eradicated the tumor within 24 hours without affecting
the normal cells.
T
he development of a technology that is capable of high-specificity targeted delivery of anti-neoplastic drugs
would be a significant breakthrough in cancer in general and ovarian cancer in particular. Although the
circulatory system can deliver a drug to every cell in the body, delivering the drug specifically inside the
tumor cell past its membrane without affecting the healthy cells remains a challenge1–3. In ovarian cancer,
intraperitoneal (IP) delivery through a surgically implanted catheter has shown improved survival rates.
However, catheter complications and toxicity have precluded widespread adoption of this invasive means of
delivery4. Current research attempts to go around these limiting factors by using nanoscale systems5–7. Often, as
immunological reagents, monoclonal antibodies are used to recognize the tumor-specific biomarker while the
nanoscale control further improves the specificity and targeted drug delivery capability in general8–10.
Nonetheless, in spite of the tremendous progress in this field during the last decades, the capability of targeted
delivery with adequately high specificity (to tumor cells) remains an important roadblock to finding a cure for
cancer.
In this paper, we present a study in which we address this challenge through a new physical concept. It exploits
(i) the difference in the electric properties of themembrane between the tumor and healthy cells and (ii) the ability
of the recently discovered body-temperature magneto-electric nanoparticles (MENs) to function as nano-con-
verters of remotely supplied magnetic field energy into the MENs’ intrinsic electric field energy11–13. Like the
conventional magnetic nanoparticles (MNs), MENs have a non-zero magnetic moment and therefore can be
controlled remotely via application of an external magnetic field. However, unlike MNs, MENs offer a new far-
reaching function, which is an energy-efficient control of the intrinsic electric fields within the nanoparticles by an
external magnetic field. This unprecedented capability is a result of the strong magneto-electric (ME) coupling in
this new class of nanostructures even at body temperature11–13. As a result, MENs introduced in a biological
microenvironment act as localized magnetic-to-electric-field nano-converters that allow remote control and
generation of the electric signals that underlie the intrinsic molecular interactions. Recently, we exploited this
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capability: (i) to achieve remotely-controlled brain stimulation in
patients with Parkinson’s Disease by applying low-energy a.c. mag-
netic fields to control the a.c. electric signals in the central nervous
system (CNS) using intravenously injected MENs and (ii) to deliver
and release on-demand (via an external field) anti-retroviral (ARV)
drug AZTTP for treatment of HIV-1 reservoirs across the blood
brain-barrier (BBB)14,15. In this study, we exploit this capability to
achieve the field-controlled specificity of the drug-loaded MENs as
required to significantly improve the state of chemotherapy.
TheMEN’s new capability to control the local electric fields remo-
tely (via magnetic fields) opens an exciting and previously unex-
plored path to exploit the intrinsic electric properties of the cell
membrane. Due to the presence of ion channels and other electric-
field driven properties, the cell membrane is an electrically polar-
izable medium. As a result, its properties can be significantly affected
by an electric field. In fact, electroporation is one such well-known
characteristic that exploits the dependence of the membrane’s por-
osity on the electric field16–21. The electroporation has been widely
studied as a means to trigger drug delivery into the cells. Through
macroscale studies (on samples with centimeter sizes) it is known
that an electric field of higher than 1000 V/cm creates sufficiently
large pores for the drug nanoformulations to penetrate through
the membrane. Our new approach was to use MENs to exploit the
promising delivery technique by scaling it down into the nanoscale.
Due to this NANO-ELECTROPORATION, magnetic-field-activated
MENs loaded with the drug and optionally with the biomarker-spe-
cific antibodies (for delivery to the tumor cells) can generate localized
fields large enough to open up the membrane pores in their prox-
imity only and thus let the drug inside the tumor cells. Because this
process is relatively energy efficient, most of the energy goes to fulfill
the main operation (of opening up the local pores, i.e. the nanoscale
electroporation) and consequently it doesn’t result in any significant
and potentially damaging energy dissipation, e.g., in terms of heat.
The interaction between the MENs and the electric system of the
membrane effectively serves as a field-controlled gate to let the drug-
loaded nanoparticles enter specifically the tumor cells only. An
artist’s view of the main hypothesis is presented in Fig. 1. In this
case, the origin of the specificity to the tumor cells is two-fold. First,
the biomarker-specific antibodies steer the drug-loaded MENs (to
which they also are attached) to the tumor cell membrane. Second,
even higher specificity is achieved due to the fact that the tumor and
healthy cells have different values of the threshold field, Hth, for the
‘‘gate’’ to open up. Indeed, it is well-known that the electric prop-
erties differ significantly between the healthy and tumor cells of the
same type22. In general, the tumor cells have substantially lower
values of the potential compared to that of the healthy cells.
Consequently, the cancer cells must also have a significantly lower
value of the threshold field for the drug-loaded MENs to enter the
cell. Considering the value for the ME coefficient a, 100 mV cm21
Oe21, according to the simple isotropic expression for the ME effect,
DP 5 aH, where P and H stand for the induced electric dipole field
and the external magnetic field, respectively, the electric field of the
order of 1000 V/cm can be generated a few nanometers away from
the MEN merely by applying a magnetic field of 10 kOe. Moreover,
the same order of magnitude electric can be generated by much
smaller magnetic fields, of the order of 100 Oe, if one takes into
account the edge effects because of the cubic symmetry of the real-
life nanoparticles, as shown below. Due to the edge effect (signifi-
cantly enhanced charge density at the edges), the electric field in the
vicinity of MENs could be amplified by a factor of 100 or more
depending on the proximity to the edge. Moreover, the edge effects
in the case of ME materials might be even further enhanced because
both the electric charge density and the effective magnetic charge
density are amplified at the edges. Ideally, after the drug-loaded
MENs penetrate into the cell cytosol through the ‘‘open’’ pores in
the membrane, the drug can be released off the MENs by further
increasing the field above the second critical value, Hr, necessary for
overcoming the drug-MEN binding energy. We described one
underlying hypothesis of this field-controlled drug release process
in a recent article14. This field strongly depends on the binding force
between the MEN and the drug and consequently can be tuned in a
large range through using different intermediate coating materials,
field excitation frequencies and treatment durations. In summary,
according to our idealistic hypothesis, there are two critical field
values, Hth and Hr, that define the drug penetration threshold
through the tumor cell membrane and the following release of the
drug into the cell cytosol, respectively. To ensure adequately high
efficacy of the uptake, we need Hr . Hth. To ensure the required
specificity of the uptake to the cancer cells only, the external applied
field, HA, needs to be higher than the release field for the tumor cells,
Hr_cancer, and lower than the threshold field for the healthy cells,
Hth_healthy. In summary, using MENs not only can provide field-
controlled delivery but also can significantly improve the specificity
to tumor (compared to the specificity defined by the monoclonal
Figure 1 | Hypothesis illustration: MENs as field-controlled nano-electroporation sites to let the drug through the cancer cell membranes.
www.nature.com/scientificreports
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antibodies alone). When combined, monoclonal antibodies and
MENs can make even a better delivery system.While the monoclonal
antibodies steer the loaded drugs towards the surface of the tumor
cells, the field-controlled MENs move the drugs across the cell mem-
brane into the cytosol.
This new high-specificity nanotechnology can be applied to the
treatment of cancer in general. In the current study, to prove our
hypothesis, we used Epithelial Ovarian Cancer (EOC). EOC has been
widely studied in the medical community23. Cytoreductive surgery
followed by chemotherapy with mitotic inhibitor Paclitaxel (PTX)
with platinum is the gold standard in treating EOC. Inmost cases, the
drug administration is intravenous (IV). Less commonly the admin-
istration is IP. As noted, there are technical considerations and lim-
itations to IP therapy, although it is more effective than IV therapy.
In either case, the specificity of the drug uptake is still relatively low
and as a result EOC remains a highly lethal malignancy. Therefore,
the current study is relevant to this field. In addition, because of the
high-specificity capability, the new nanotechnology can be used for
targeted treatment of both localized and metastasized tumor cells.
Finally, by its fundamental nature, this nanotechnology can be
applied to a wide range of other cancers.
Results
Through the described in-vitro studies on human ovarian carcinoma
cell (SKOV-3) and healthy ovarian cell (HOMEC) lines, we demon-
strated that high-specificity uptake of PTX-loaded 30-nmCoFe2O4@
BaTiO3 MENs could be triggered by a low-energy 30-Oe d.c. remote
magnetic field with relatively small or negligible heat dissipation24–26.
Through kinetics studies we confirmed that the drug penetrated
through the tumor cell membrane and eradicated the majority of
the cells within a 24-hour period without affecting the surrounding
healthy cells. Finally, to demonstrate the applicability of this nano-
technology to other cancers, we conducted a parallel study using a
multidrug resistant (MDR) uterine sarcoma cell type MES-SA/
DX527–29.
The procedures to fabricate the nanoparticles with different sets of
coatings and drug loadings are described in Section Methods. The
release threshold field, Hr, could be controlled in a wide range, from
10 Oe to substantially over 200 Oe, through different intermediate
layers/coatings. A comparative analysis of the effect of the intermedi-
ate layer type on Hr is summarized in Fig. S1. By default, in order to
provide adequate coupling between the MENs and Flutax-2 (to pro-
vide the initial release field of the order of 30 Oe), before being loaded
with the drug, theMENswere coated with 3-Angstrom thick glycerol
monooleate (GMO) layers. The zeta-potential and size of the MENs,
GMO-MENs, HER2-GMO-MENs, and PTX-GMO-MENs are
shown is Table S3. For the purpose of a comparative analysis, we
studied the following combinations of nanoparticles: (i) MENs
loaded with PTX, (2)MENs loaded with PTX and the popular cancer
biomarker HER-2 antibody, (3) free PTX, and (4) conventional MNs
loaded with PTX. As the conventional MNs, 30-nmmagnetite nano-
particles were used.
Field-controlled drug release by MEN-based carriers.Drug release
from these different MEN-based combinations was triggered by a
magnetic field at different strengths and frequencies, according to the
physics described in our earlier paper on the release of ARV drug
AZTTP for treatment of HIV-1 virus in the brain14. The pellet
obtained after the drug loading procedure was washed thrice with
the phosphate-buffered saline (PBS) buffer, to remove any residual
unbounded drug. The drug-loaded-MENs’ pellet was added to 1 ml
of the PBS buffer in a vial and subjected to a d.c. or a.c. magnetic field
using a pair of Helmholtz coils connected to a d.c. or a.c. power
supply, respectively. After exposing the vial to any magnetic field
environment under study, the supernatant was obtained by
spinning the sample at 3,000 rpm for 5 minutes and at 10uC. The
supernatant was measured for the amount of the released drug
spectrophotometerically through the absorbance at the PTX
maximum wavelength of 230 nm30.
The results of the field-controlled drug release spectrophotometry
(absorption) experiments are summarized in Fig. 2. Fig. 2A shows
the percentage of the drug release after a 1-minute exposure to a
magnetic field at three strengths, 12, 44, and 66 Oe, respectively,
for three different frequencies, 0, 100, and 1000 Hz, respectively.
As expected (see explanation above), for each frequency, there was
a critical field, Hr, at which the drug release was significantly boosted.
The increase of the frequency in the range up to 1000 Hz under study
increased the release efficacy (by over 40%) especially at the low field
range. Fig. 2B illustrates the kinetics of the field-strength-frequency
dependence of the release for the five values of the field exposure
times, 1, 5, 10, 60, and 120 minutes, respectively. The quantitative
values are also presented in Table S1. For every exposure time setting,
a fresh solution with PTX-loaded GMO-coated MENs was used.
The field-triggered drug release was also confirmed through atomic
force microscopy (AFM), Fourier Transform Infra-Red (FTIR),
mass spectrometry, and X-ray diffraction (XRD) pattern studies.
The results are summarized in Fig. S2, Fig. S3, Fig. S4, and Fig. S5,
respectively.
Field-controlled drug uptake by tumor cells through the MEN-
induced NANO-ELECTROPORATION. Fluorescent cellular drug
uptake experiments were performed on the SKOV-3 cells using the
four different drug forms under study, (i) free Flutax-2, (ii) Flutax-2
bound to the conventional MNs, (iii) Flutax-2 bound to GMO-
MENs, and (iv) Flutax-2 bound to HER-2-GMO-MENs, respec-
tively. The obtained Flutax-2 concentration was normalized to the
protein amount. The results of the experiment performed in
triplicates are shown in Fig. 3. These results showed that the drug
Figure 2 | Photo-absorption measurements of the release kinetics.
www.nature.com/scientificreports
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uptake increased by a factor of five for the drug carried by field-
controlled MENs compared to the drug driven by the HER-2
antibodies. The details of the related fabrication and measurements
are described in Section Methods.
Confocal microscopy to visualize the internal drug localization in
SKOV-3 cell lines. To visualize the internal localization of each of
the four drug forms under study, (i) free Flutax-2, (ii) Flutax-2-
GMO-MENs, (iii) Flutax-2-HER-2, and (iv) Flutax-2-MNs,
respectively, in SKOV-3 cell lines, we conducted the following
fluorescence imaging experiments.
Magnetic field dependence of drug uptake in cancer and healthy
cells. To understand the field dependence of the described process,
we performed the cellular drug uptake experiments under a varying
magnetic field strength on both cancer ovarian (SKOV-3) and
healthy ovarian cell (HOMEC) lines. The HOMEC cells were
cultured according to the same procedures that are described for
the SKOV-3 cells in Section Methods. As a control, the cells with
GMO-MENs only (without Flutax-2) were treated under the
equivalent conditions. The cell culture plates with the MENs and
drug-GMO-MENs were exposed to three different field strengths,
5, 15, and 30 Oe, respectively. The results are summarized in Fig. 5.
The measurements showed that as the field was increased above
approximately 30 Oe, the drug penetration into the cancer cells
(SKOV-3) greatly increased. On the other hand, it can be noted
that the drug barely affected the healthy cells (HOMEC) in the
field range under study.
Cancer cell viability test. After we confirmed that the drug-loaded
MENs in the vicinity of the cancer cells indeed acted as a field-
controlled valve to let the drug in (due to the effective nano-
electroporation effect according to our hypothesis), we studied the
viability of the cancer cells for different combinations of the drug and
the carrier after the drug penetrated through the cell membrane.
(Here, maintaining the remote field at 30 Oe provided the
specificity to the cancer cells or, in other words, ensured that the
healthy cells were intact.) The confocal images that were obtained
after a 24-hour field treatment are in Fig. 6. The three key
combinations of the carrier included (i) no particle, (ii) HER-2-
GMO-MENs (Note: Here, HER-2 stands for the HER-2 biomarker
antibody), and (iii) GMO-MENs, respectively. Accordingly, the three
images (from left to right) in Fig. 6A show the morphology of the
cancer cells after 24-hour treatment by (i) the free drug (with no
particle carrier), (ii) drug-HER-2-GMO-MENs with no field
applied, and (iii) drug-GMO-MENs in a 30-Oe d.c. field. The three
control images in Fig. 6B show the morphology of the cancer cells
after the 24-hour treatment by the same three combinations of the
carrier with no drug present. In addition, we conducted the confocal
imaging and the trypan-blue cell viability tests on both SKOV-3 and
HOMEC cell lines after 24- and 36-hour field treatment. The
confocal images are shown in Fig. S6, while the tryphan-blue
viability data are summarized in Table S2.
In-vitro cytotoxicity assay.To determine the cytotoxicity of the GMO-
MENs on SKOV-3 cells, a quantitative colorimetric XTT (sodium 2,
3,-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)-carbonyl]-
2H-tetrazolium inner salt) assay was performed. The assay is based on
the reduction of XTT tetrazolium salt by the viable cells to form orange
colored formazan derivative. In this assay, 13 105 cells were seeded per
well in a 96-well plate and incubated at 37uC for 24 hours. After the
incubation, the cell medium was replaced by the medium containing
the GMO-MENs at a differential concentration of 0–100 mg/ml per
well and the cells were incubated for another 24-hour period. Then, the
cell medium was replaced with a fresh one and washed with the PBS
buffer and cell viability assay was performed by adding 50 ml per well of
XTT-activated solution from the XTT test kit supplied by ATCC and
incubate for 4 hours at 37uC. The experiments were performed in
triplicates. As summarized in Fig. S7, no significant cytotoxicity was
observed.
Heat-dissipation due to field-treatment withMENs. In this experi-
ment, the temperature was measured locally via Infra-red (IR)
camera FLIR-i3 on the surface of both cancer (SKOV-3) and
healthy (HOMEC) ovarian cells before and after a field treatment,
as shown in Fig. S8. The experimental error of the setup was
approximately 1/2 2 Celsius degrees of the infrared camera. The
magnetic field of 30 Oe was applied for a 24-hour period. No
significant heat dissipation was observed as a result of the field
treatment. The negligible heat dissipation (compared to the
conventional method) is a consequence of the intrinsic nature of
the magneto-electric coupling which resulted in the relatively high
high-efficacy control of intrinsic electric fields by external magnetic
fields.
Universal applicability: MENs-triggered drug uptake in MDR cell
MES-SA/DX5. To demonstrate the applicability of the new
nanotechnology to other cancers, we conducted a parallel study on
a well-known multi-drug resistant cell line MES-SA/DX5. The
results of the confocal microscopy imaging of the uptake of the
same drug (Flutax-2) by this cell type is shown in Fig. S9. For
comparison, the following four different drug-delivery-system
combinations were studied: (a) no drug, (b) free Flutax-2, (c)
Flutax-2-GMO-MENs with no field. (d) Flutax-2-GMO-MENs
with 30 Oe field.
Figure 3 | Drug uptake by cancer cells via different carriers.
www.nature.com/scientificreports
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Discussion
The results of the above experiments confirmed our hypothesis that
MENs loaded with the drug PTX could serve as high-specificity
remotely controlled (via magnetic fields) delivery nanosystems to
treat EOC. We believe that this function was achieved due to the
localized electroporation effects induced by the MENs in the vicinity
of the cancer cell membranes when exposed to an external magnetic
field. To refer to the effect at the nanoscale, we used the new ter-
minology, ‘‘NANO-ELECTROPORATION.’’ The experiments were
conducted to separate the two core field-dependent processes
according to the main hypothesis. These two processes are defined
by the following two critical fields, respectively: (i) the threshold field,
Hth, for MENs to penetrate through the cancer cell membrane to
deliver the drug into the cell cytosol (by means of the field-induced
localized nano-electroporation effect in the vicinity of MENs); and
(ii) the release field, Hr, that triggers unloading of the drug after the
drug-loaded MENs penetrated into the cell. The specificity to the
cancer cells was defined not just by the typical HER-2 antibody
chemistry but also by the new physical mechanism that relied on
the significant difference in the threshold electric field between the
healthy and cancer cells. This threshold field was measured to be of
the order of 30 Oe and above 200 Oe for the SKOV-3 and HOMEC
cells, respectively. Moreover, these experiments indicated that this
remote-magnetic-field-triggered electric-field-defined specificity to
the cancer cells resulted in a more pronounced eradication of the
cancerous cells. The percentage of the cell-penetrated drug was
increased by at least a factor of five compared to the traditional
antibody-mediated targeting (figure 4). In addition, after the drug
was efficiently transferred through the tumor cell membrane by the
field-controlled MEN-initiated nano-electroporation, eradication of
the majority of the cancer cells (without affecting the healthy cells)
was observed within a 24-hour period of a low-energy 30-Oe treat-
ment (figures 5 and 6).
To achieve adequately high efficacy of the drug delivery, the value of
the release field, Hr, was chosen to be higher than the value of the
threshold field to penetrate through the membrane, Hth, for the cell of
the same type. It can be reminded that the release field is defined by the
binding force between the MEN and the drug, while the penetration
Figure 4 | Confocal microscopy imaging of the drug uptake by SKOV-3 with different drug carriers.
Figure 5 | Field dependence of the drug uptake by SKOV-3 and HOMEC cells.
www.nature.com/scientificreports
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threshold field, Hth, is mostly determined by the electric properties of
the cell membrane that lead to the localized electroporation effects. We
could control the release field by the proper selection of the intermedi-
ate layer between the drug and the MEN. (As summarized in Fig. S1,
by choosing different intermediate layers we could control the initial
release field in a wide range, from less than 10 Oe to over 200 Oe. By
default, a 2-nm thin GMO layer was used as the intermediate layer.) In
addition, the release field depended on the field treatment duration and
the frequency of the a.c. field, as shown in Fig. 2 (bottom). For example,
as shown in Fig. 2A, the spectrophotometry measurements of the
absorbance at 230 nm (for PTX) indicated that only 1 minute of field
treatment at a 66-Oe d.c. magnetic field was sufficient to release over
95% of the drug. As shown in Fig. 2B, the same release efficacy (of over
95%) could be achieved also at an 1000-Hz a.c. field at a smaller field
strength of 44 Oe in 2 hours of treatment. This complex dependence
can be explained by the fact that the external field effectively reduces
the energy barrier that holds together the MEN and the drug while an
increase of the treatment duration increases the temperature-induced
probability to overcome the barrier or, in other words, break the bond.
As for the frequency dependence, in our previous paper we explained
the underlying physics through field torque effects that break the bond
as the frequency increases14. Here, it can be mentioned that although
using a.c. external magnetic fields could indeed add another knob to
control the targeted delivery, in this study to focus on the proof of the
main hypothesis, as illustrated in Fig. 1, we followed the d.c. field
scenario. The d.c.-field-controlled drug release kinetics was confirmed
also through AFM, FTIR, and Mass Spectrometry, and X-ray diffrac-
tion pattern studies, as shown in Fig. S2, Fig. S3, Fig. S4, and Fig. S5,
respectively. As confirmed by infrared measurements of the cellular
surface temperature (Fig. S8), theMENs’s field action didn’t trigger any
significant temperature changes in the field and frequency range under
study. This is in agreement with the fact that the MENs-induced
delivery is a relatively energy-efficient process (because of the strong
intrinsic magneto-electric coupling) which causes only negligible heat
dissipation.
As for the penetration threshold field, Hth, we found that for the
cancer cell membrane the value was of the order of 30 Oe, i.e. less than
the d.c. release field (for the default MEN carriers coated with GMO)
of 60 Oe. Again, according to the main hypothesis, to ensure the
specificity to the cancer cells, it is important to maintain the remote
field above the release value for the tumor cells but lower than the
threshold value for the healthy cells. Indeed, at a 30-Oe external d.c.
field, the drug couldn’t penetrate through the healthy cell membrane
for the 24-hour treatment duration, which confirmed that the thresh-
old field for the drug-loaded MENs to penetrate into the healthy cell
exceeded 30 Oe during the entire treatment (figure 5). Specifically, the
GMO-MENs field-treated HOMEC cells showed negligible drug
intake per 1 mg of the cellular protein content. The value was 0.18
6 0.07, 0.30 6 0.04, and 0.55 6 0.16% for the field strength of 5, 15,
and 30 Oe, respectively. On the contrary, SKOV-3 cells showed sig-
nificantly higher values of the drug intake, which was 1.506 0.41, 2.36
6 0.48, and 10.41 6 1.54% for the field strength of 5, 15, and 30 Oe,
respectively. It can be noted that after a 24-hour 30-Oe field treatment
by GMO-MENs, approximately 95 and 34% of HOMEC and SKOV-3
cells, respectively, remained viable (Fig. S6). When the treatment was
extended to 36 hours, the percentage of viable cells fell to approxi-
mately 85 and 10% for HOMEC and SKOV-3 cells, respectively.
These results indicate that further field and frequency optimization
could be used to perfect the treatment results.
Least but not last, the cytotoxicity measurements with the stand-
ard XTT assay performed on SKOV-3 cells at different concentra-
tions of MENs showed no significant toxicity even at the highest
nanoparticles concentration value of 100 mg/ml (figure S6). The
chart shows the results of XTT Assay performed on SKOV-3 cells
at different concentrations of GMO-MENs.
Finally, the parallel study on MDR cell MES-SA/DX5 proved the
applicability of the new nanotechnology to other cancers (figure S8).
It might be worth noting that due to the overexpressed transmem-
brane poteints, e.g. P-glycoprotein, this cell type is known to be
relatively impenetrable for many popular chemotherapy drugs,
which makes the finding even more significant31,32.
Methods
Preparation of CoFe2O4-BaTiO3 coreshell MENs. CoFe2O4-BaTiO3 core shell
MENs were prepared according to the following conventional procedure33. As the
first step, CoFe2O4 particles were prepared by the standard hydrothermal method,
Figure 6 | Confocal imaging of SKOV-3 cell viability after treatment by different drug-carrier combinations with and without field.
www.nature.com/scientificreports
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according to which 0.058 g of Co(NO3)2.6H20 and 0.16 g of Fe(NO3)3.9H20 were
dissolved in 15 ml of distill water and 0.2 g of polyvinylpyrrolidone was dissolved in
5 ml of aqueous solution containing 0.9 g of sodium borohydride at 120uC for 12
hours. Then, precursor solution of BaTiO3 was prepared by mixing 30 ml of aqueous
solution containing 0.029 g of BaCO3 and 0.1 g of citric acid with 30 ml of ethanolic
solution containing 1 g of citric acid and 0.048 ml of titanium (IV) isopropoxide.
Coreshell CoFe2O4-BaTiO3 MENs were prepared by mixing 0.1 g of CoFe2O4
nanoparticles in the BaTiO3 precursor solution and the mixture was sonicated for
2 hrs. Once the CoFe2O4 nanoparticles were thoroughly dispersed, the mixture was
dried on the hot plate at 60uC overnight while continuously stirring. The dried
powder was subjected to 780uC for 5 hrs. in a furnace (CMF-1100) and cooled at 52uC
per minute to obtained the coreshell MENs of ,30 nm diameter. The particles size
distribution was measured using dynamic light scattering method (Malvern-
Zetasizer).
Preparation of GMO-MENs. In-order to load the PTX drug onto theMENs’ surface,
the nanoparticles were first coated with GMO to adjust the release field at about
30 Oe as required for this application. To achieve this, 1 mg of GMO was added to
5 mg ofMENs in 5 ml of the PBS buffer. Themixture was then incubated for 12 hours
while being slowly rotated in order to achieve uniform coating. Upon completion of
the incubation process, the nanoparticles were centrifuged at 20,000 rpm for 20
minutes at 10uC. The pellet was washed in ethyl acetate:acetone (70530) solution and
re-centrifuged. The washing process was repeated thrice to completely remove the
excess unbound GMO. Finally, the obtained pellet was lyophilized for 48 hours and
stored for further use. The results of the energy dispersion spectrometry (EDS) that
depict the materials composition of GMO-MENs are summarized in Fig. S10.
Preparation of HER-2 biomarker antibody conjugated GMO-MENs. HER-2
biomarker antibodies were covalently attached onto the GMO-MENs’ surface
according to the protocol described byKocbek et al34. In-order to covalently attach the
HER-2 antibodies, the nanoparticle surface was preliminarily functionalized. For this,
1 mg of GMO-MENs were added to 500 ml of the PBS buffer (pH 7.4). To this
solution, 25 ml of N-(3-Dimethylaminopropyl)-N9-ethyl-carbodiimide
hydrochloride (EDC) and 25 ml of N-hydroxysuccinimide (NHS), at 1 mg/ml
concentration in the PBS buffer (pH 7.4) were added. The solution was incubated for
4 hours at room temperature while being stirred slowly. Then, the sample was
centrifuged at 14,000 rpm for 10 minutes at 10uC and the pellet was washed three
times with 1 ml of the PBS buffer (pH 7.4). To bind HER-2 antibodies to the
functionalizedMENs, 10 ml of the antibodies (1 mg/ml) was added to the pellet along
with 300 ml of the PBS buffer (pH 7.4). The solution was incubated for 2 hours while
being rotated slowly and kept further at 4uC overnight. The solution was centrifuged
at 14,000 rpm for 10 minutes at 10uC. The pellet was washed thrice with 1 ml of the
PBS buffer (pH 7.4) to remove any excess antibody. The supernatant was collected to
determine the amount of the unconjugated HER-2 protein by comparing to the
standard plot. A standard calibration plot for HER-2 was obtained by varying the
concentration in the range of 1.25–10 mg/ml using Bio-Rad protein assay kit (Braford
method) through measuring the absorbance at 595 nm using spectrophotometer
Cary-100 (figure S11). The percentage of the conjugated HER-2 was obtained using
the following expression: the percentage of HER-2 conjugated 5 (the total amount of
HER-2 added – the amount of the unconjugated HER2 present in the supernatant) 3
100. The results indicated that over 70% of the HER-2 antibodies were conjugated to
the GMO-MENs’ surface.
Preparation of PTX-MENs, PTX-GMO-MENs and PTX-HER-2-GMO-MENs.
After 50 mg of PTX drug was added to the solution of 900 ml of the modified PBS
(MPBS) buffer and 100 ml of the desired MEN combination (i.e., MENs, GMO-
MENs, and HER-2-GMO-MENs at a 5 mg/ml concentration), the solution was
incubated for 3 hours while stirred slowly to obtain uniform binding. Then, the
solution was centrifuged at 14,000 rpm for 10 minutes at 10uC to remove any
unbounded drug. The supernatant was isolated and absorbance was measured
spectrophometrically at 230 nm using Cary-100 UV-VIS spectrophotometer30. The
PTX loading percentage is shown in Fig. S12. A standard calibration plot for PTXwas
obtained by varying the drug concentration from 5 to 80 mg in 1 ml of the MPBS
solution and the absorbance was measured at 230 nm. The absorption maxima and
the standard linear calibration plot of PTX at different drug concentration values are
shown in Fig. S13.
Cell culture experiments. Cell culture experiments were performed using human
ovarian carcinoma cell line (SKOV-3) purchased from American Type Culture
Collection (Manassas, VA) and were cultured in McCoy’s 5A medium (Life
Technologies, NY) supplemented with 10% fetal bovine serum (Sigma-Alrich) and
1% penicillin-streptomycin (science-cell). Human Ovarian Microvasicular
endothelial cells (HOMEC) from ScienceCell (Carisbad, CA) and were cultured in
endothelial cell medium with endothelial cell growth supplement (1%), fetal bovine
serum (5%), and penicillin-streptomycin (1%). All the cells were cultured at 37uC cell
incubator with a 5% CO2 and humidified atmosphere.
Fluorescence measurements and confocal imaging of drug uptake by SKOV-3
cells for different drug-carrier combinations. Cellular drug uptake measurements
and fluorescence imaging were performed using an Oregon GreenH 488 paclitaxel
(also called Flutax-2). The experiments were performed in dark. For the fluorescence
measurements, the SKOV-3 cells were cultured in 24-well plate at a density of 2 3
105 cell per well. After 24-hour incubation at 37uC, the cell mediumwas replaced with
1 ml/well of the medium containing either one of the four desired drug forms. The
concentration of Flutax-2 was normalized to 0.75 mM (1.76 mg/ml) for all the
combinations. The cell culture plate was returned to the incubator and incubated for
10 hours. In addition, a set of controls containing no drug for all the combinationswas
cultured under similar conditions. The cell culture plates containing the Flutax-2-
MNs and Flutax-2-GMO-MENs were kept under a 30-Oe field. Upon completion of
the 10-hour incubation process, the cells were removed from incubator and the cell
culture mediumwas discarded. The cells were washed with ice-cold PBS buffer thrice.
Then, 1 ml of dimethyl sufloxide (DMSO) was added to each well and incubated for 2
hours at 37uC. After two hours, a rubber policeman was used to ensure the complete
removal of the attached cells. The solution was centrifuged at 14,000 rpm for 10
minutes at 4uC to obtain the cell lysate. The cell lysate along with the in-taken Flutax-
2-GMO-MENs was collected and measured for the fluorescence of Flutax-2 (using
BioTek instruments, synergy HT) at lex 5 496 nm and lem 5 524 nm to determine
the concentration. All the fluorescence measurements were recorded by subtracting
the corresponding controls to adjust the background fluorescence from the cellular
components. The protein content of the cell lysate was determined using Bio-Rad
protein assay kit (Braford method) by measuring the absorbance at 595 nm using a
Cary 100 UV-VIS spectrophotometer.
As for the imaging studies, the cells were cultured on glass cover slips (1 3 1 in2)
pre-coated with the poly-L-Lysine (used as a cell adhesion promoter) in a 6-well cell
culture plate at a density of 5 3 104 were cultured and let rested for about 10 minutes.
Then, 2 ml of Cell medium was added along the walls of the wells. The cell culture
plate was incubated for 24 hours at 37uC. The cells were supplied with the fresh cell
medium that contained either of the four drug forms under study normalized to the
0.75 mM(1.76 mg/ml) of Flutax-2 concentration. The cell plate containing the Flutax-
2-GMO-MENs was kept under a 30-Oemagnetic field. The cell plates were incubated
for 10 hours at 37uC.After the incubation process, cover slips were washed three times
with the PBS buffer and fixed with 4% paraformaldehyde for 30 minutes followed by
washing thrice with the PBS buffer. The cover slips were mounted onto a glass slide
using a mounting medium (ProLong Gold Antifade Reagent). The excess mounting
medium was removed by placing a small piece of Whatman paper around the edges.
After the samples were dried for 2 hours, they were imaged through confocal
microscopy (TCS SP2, Leica Microsystems, Germany) at 488 nm (100%) illusion of
an argon-ion laser using 603 oil immersion objectives with a high numeric aperture
and 13 confocal electronic zoom settings to visualize cells. Flutax-2 calibration plot is
shown in Fig. S14.
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